The latest revision to China's Regulation for Supervision and Administration of Medical Devices (RSAMD) – State Council Order No 739 – does not do enough to help foreign medtech innovators gain access to the Chinese market.
That is the contention of law firm Ropes & Gray, in a whitepaper compiled after the “2021 Medtech Regulatory Affairs Roundtable,” hosted jointly by the law firm and the consultancy...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?